KALA BIO, Inc. (KALA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, KALA BIO reported revenue of $0. Net income was -$27.0M, or -$165.50 per diluted share. Operating activities generated -$32.0M of cash. At fiscal year end, KALA BIO held $9.5M in total assets against $2.5M in total liabilities, including $7.6M of cash and equivalents.
Open the full interactive KALA BIO financials → Quarterly statements, key ratios, valuation history and price charts.
KALA BIO Key Stats
| Share Price | $0.26 |
|---|---|
| Market Cap | $19,281 |
| 52-Week Range | $0.26 – $75.50 |
| Shares Outstanding | 74,159 (basic, 2026 Q2) |
KALA BIO Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | $11.2M | $3.9M | $0 | $0 | $0 |
| Operating Income | -$96.2M | -$130.2M | -$81.7M | -$39.7M | -$41.0M | -$39.2M |
| Pre-Tax Income | -$104.3M | -$142.6M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$104.3M | -$142.6M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Diluted EPS | -$4975.00 | -$5475.00 | -$1474.00 | -$867.50 | -$507.50 | -$165.50 |
KALA BIO Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.6M | $686,000 | -$1.6M | -$1.6M |
| Diluted EPS | -$53.50 | $0.08 | -$0.14 | -$21.32 |
KALA BIO Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.3M | $92.1M | $70.5M | $50.9M | $51.2M | $7.6M |
| Current Assets | $171.4M | $124.4M | $85.9M | $52.9M | $52.8M | $9.5M |
| Total Assets | $221.6M | $139.4M | $86.8M | $55.9M | $55.5M | $9.5M |
| Current Liabilities | $22.2M | $37.4M | $25.7M | $8.3M | $17.0M | $2.5M |
| Total Long-Term Debt | $75.0M | $80.0M | $42.9M | $34.2M | $30.4M | — |
| Total Liabilities | $121.6M | $122.6M | $67.8M | $48.4M | $43.2M | $2.5M |
| Shareholders' Equity | $100.0M | $16.8M | $19.0M | $7.5M | $12.3M | $7.0M |
KALA BIO Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$90.7M | -$108.2M | -$78.9M | -$27.9M | -$29.4M | -$32.0M |
| Cash From Investing | -$78.2M | $70.8M | $62.7M | -$429,000 | -$208,000 | -$15,000 |
| Cash From Financing | $160.6M | $42.6M | -$7.9M | $8.5M | $29.9M | -$11.6M |
Figures from KALA BIO's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full KALA BIO financials page for every line item.
KALA BIO Company Profile
| Ticker | KALA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Arlington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001479419 |
Frequently Asked Questions
What was KALA BIO's revenue in fiscal 2025?
KALA BIO (KALA) reported revenue of $0 for fiscal 2025.
What is KALA BIO's annual revenue history?
KALA BIO's annual revenue by fiscal year: 2020: $6.4M; 2021: $11.2M; 2022: $3.9M; 2023: $0; 2024: $0; 2025: $0.
What was KALA BIO's net income in fiscal 2025?
KALA BIO reported net income of -$27.0M for fiscal 2025.
What was KALA BIO's earnings per share (EPS) in fiscal 2025?
KALA BIO's diluted EPS was -$165.50 for fiscal 2025 (adjusted for any later stock splits).
What was KALA BIO's revenue last quarter?
In its most recent reported quarter (2026 Q2), KALA BIO reported revenue of $0.
How many shares of KALA BIO are outstanding?
KALA BIO reported a weighted average of 74,159 basic shares outstanding in 2026 Q2.
What is KALA BIO's market cap?
Based on its latest closing price, KALA BIO (KALA) has a market capitalization of about $19,281.
When does KALA BIO's fiscal year end?
KALA BIO's fiscal year end, as registered with the SEC, is December 31.
Where is KALA BIO headquartered?
KALA BIO lists its business address in Arlington, Massachusetts in its SEC filings.